Poly(ADP-ribose)polymerase inhibition decreases angiogenesis

Biochemical and Biophysical Research Communications

Volumn 350, Issue 4, 2006, Pages 1056-1062

  Rajesh, Mohanraj ^a   Mukhopadhyay, Partha ^a   Godlewski, Grzegorz ^a   Bátkai, Sándor ^a   Haskó, György ^b   Liaudet, Lucas ^c   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

1,5 Isoquinolinediol (IQD); 5 Aminoisoquinolinone hydrochloride (5 AIQ); Angiogenesis; Aortic ring assay; Cancer; HUVEC; Migration; Poly(ADP ribose)polymerase (PARP); Proliferation; Tube formation

Indexed keywords

1,5 ISOQUINOLINEDIOL; 5 AMINOISOQUINOLINONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUINOLINE DERIVATIVE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; AORTA; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; RETINOPATHY;

CELL MOVEMENT; CELL PROLIFERATION; CELLS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; ISOQUINOLINES; NEOVASCULARIZATION, PHYSIOLOGIC; POLY(ADP-RIBOSE) POLYMERASES; QUINOLINES;

EID: 33750046338     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.09.160     Document Type: Article

References (33)

1. Virag L., and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54 (2002) 375-429
2. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug. Discov. 4 (2005) 421-440
3. Schreiber V., Dantzer F., Ame J.C., and de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7 (2006) 517-528
4. Delaney C.A., Wang L.Z., Kyle S., White A.W., Calvert A.H., Curtin N.J., Durkacz B.W., Hostomsky Z., and Newell D.R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6 (2000) 2860-2867
5. Tentori L., Portarena I., Vernole P., De Fabritiis P., Madaio R., Balduzzi A., Roy R., Bonmassar E., and Graziani G. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother. Pharmacol. 47 (2001) 361-369
6. Canan Koch S.S., Thoresen L.H., Tikhe J.G., Maegley K.A., Almassy R.J., Li J., Yu X.H., Zook S.E., Kumpf R.A., Zhang C., Boritzki T.J., Mansour R.N., Zhang K.E., Ekker A., Calabrese C.R., Curtin N.J., Kyle S., Thomas H.D., Wang L.Z., Calvert A.H., Golding B.T., Griffin R.J., Newell D.R., Webber S.E., and Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. 45 (2002) 4961-4974
7. Tentori L., Portarena I., Bonmassar E., and Graziani G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ. 8 (2001) 457-469
8. Calabrese C.R., Batey M.A., Thomas H.D., Durkacz B.W., Wang L.Z., Kyle S., Skalitzky D., Li J., Zhang C., Boritzki T., Maegley K., Calvert A.H., Hostomsky Z., Newell D.R., and Curtin N.J. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. 9 (2003) 2711-2718
9. Calabrese C.R., Almassy R., Barton S., Batey M.A., Calvert A.H., Canan-Koch S., Durkacz B.W., Hostomsky Z., Kumpf R.A., Kyle S., Li J., Maegley K., Newell D.R., Notarianni E., Stratford I.J., Skalitzky D., Thomas H.D., Wang L.Z., Webber S.E., Williams K.J., and Curtin N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96 (2004) 56-67
10. Curtin N.J., Wang L.Z., Yiakouvaki A., Kyle S., Arris C.A., Canan-Koch S., Webber S.E., Durkacz B.W., Calvert H.A., Hostomsky Z., and Newell D.R. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res. 10 (2004) 881-889
11. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., and Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
12. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., and Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
13. Graziani G., Battaini F., and Zhang J. PARP-1 inhibition to treat cancer, ischemia, inflammation. Pharmacol. Res. 52 (2005) 1-4
14. Graziani G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 52 (2005) 109-118
15. Cheng C.L., Johnson S.P., Keir S.T., Quinn J.A., Ali-Osman F., Szabo C., Li H., Salzman A.L., Dolan M.E., Modrich P., Bigner D.D., and Friedman H.S. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer Ther. 4 (2005) 1364-1368
16. Haince J.F., Rouleau M., Hendzel M.J., Masson J.Y., and Poirier G.G. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol. Med. 11 (2005) 456-463
17. Tentori L., Leonetti C., Scarsella M., Muzi A., Mazzon E., Vergati M., Forini O., Lapidus R., Xu W., Dorio A.S., Zhang J., Cuzzocrea S., and Graziani G. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 20 (2006) 1709-1711
18. De Soto J.A., Wang X., Tominaga Y., Wang R.H., Cao L., Qiao W., Li C., Xu X., Skoumbourdis A.P., Prindiville S.A., Thomas C.J., and Deng C.X. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int. J. Biol. Sci. 2 (2006) 179-185
19. De Soto J.A., and Deng C.X. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?. Int. J. Med. Sci. 3 (2006) 117-123
20. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br. J. Cancer 94 (2006) 341-345
21. Racz I., Tory K., Gallyas Jr. F., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., and Literati-Nagy P. BGP-15-a novel poly(ADP-ribose) polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63 (2002) 1099-1111
22. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., Hasko G., and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300 (2002) 862-867
23. Pacher P., Liaudet L., Mabley J.G., Cziraki A., Hasko G., and Szabo C. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int. J. Mol. Med. 17 (2006) 369-375
24. M. Rajesh, P. Mukhopadhyay, S. Batkai, G. Godlewski, G. Hasko, L. Liaudet, P. Pacher, Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis, Biochem. Biophys. Res. Commun. (2006) in press, doi: 10.1016/j.bbrc.2006.09.049.
25. Cattaneo M.G., Pola S., Francescato P., Chillemi F., and Vicentini L.M. Human endostatin-derived synthetic peptides possess potent antiangiogenic properties in vitro and in vivo. Exp. Cell Res. 283 (2003) 230-236
26. Rajesh M., Kolmakova A., and Chatterjee S. Novel role of lactosylceramide in vascular endothelial growth factor-mediated angiogenesis in human endothelial cells. Circ. Res. 97 (2005) 796-804
27. Nicosia R.F., and Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab. Invest. 63 (1990) 115-122
28. Alano C.C., Kauppinen T.M., Valls A.V., and Swanson R.A. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc. Natl .Acad. Sci. USA 103 (2006) 9685-9690
29. C. Szabo, P. Pacher, A. Swanson, Novel modulators of poly (ADP-ribose) polymerase, Trends Pharmacol. Sci. (2006) in press.
30. Tamargo R.J., Bok R.A., and Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51 (1991) 672-675
31. Zheng L., Szabo C., and Kern T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53 (2004) 2960-2967
32. Obrosova I.G., Minchenko A.G., Frank R.N., Seigel G.M., Zsengeller Z., Pacher P., Stevens M.J., and Szabo C. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int. J. Mol. Med. 14 (2004) 55-64
33. Pacher P., and Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid. Redox Signal. 7 (2005) 1568-1580